Publicacions (60) Publicacions de Delia D'Avola

2023

  1. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 869-879

  2. Pathophysiology of attacks in acute hepatic porphyrias

    Medicina Clinica

2022

  1. Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

    Bioengineering and Translational Medicine, Vol. 7, Núm. 3

  2. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1185-1198

  3. Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer

    Gut, Vol. 71, Núm. 10, pp. 2069-2080

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

  2. Intratumoral heterogeneity and clonal evolution in liver cancer

    Nature Communications, Vol. 11, Núm. 1

2019

  1. A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites

    Histopathology, Vol. 74, Núm. 5, pp. 718-730

  2. Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know

    CardioVascular and Interventional Radiology, Vol. 42, Núm. 9, pp. 1262-1270

2018

  1. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma

    Oncogene, Vol. 37, Núm. 27, pp. 3740-3752

  2. High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil

    Liver Transplantation, Vol. 23, Núm. 4, pp. 498-509

  2. Conversion from calcineurin Inhibitor-Based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation

    Annals of Transplantation, Vol. 22, pp. 141-147

  3. Immune checkpoint inhibitors for the treatment of hepatocellular carcinoma

    Immunotherapy of Hepatocellular Carcinoma (Springer International Publishing), pp. 51-68

  4. Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma

    RESISTANCE TO MOLECULAR THERAPIES FOR HEPATOCELLULAR CARCINOMA (SPRINGER INTERNATIONAL PUBLISHING AG), pp. 25-43

  5. NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma

    Oncotarget, Vol. 8, Núm. 25, pp. 40967-40981

  6. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Controlling Diabetes after Liver Transplantation: Room for Improvement

    Transplantation, Vol. 100, Núm. 10, pp. e66-e73

  2. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  3. Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective

    Clinical Liver Disease, Vol. 8, Núm. 4, pp. 100-104